
Keywords: ADCC, antibody-de-pendent cytotoxicity; ALM, alemtuzumab; CLL, chronic lymphocytic leukemia; CCP, complement control protein; CDC, complement-dependent cytotoxicity; MAC, membrane attack complex; NIP, 5-iodo-4-hydroxy-3-nitrophenacetyl; OFA, ofatumumab; r